Skip to main content
. 2021 Oct 20;13(11):1745. doi: 10.3390/pharmaceutics13111745

Figure 1.

Figure 1

Time-course profiles of Exendin-4 concentrations in plasma (A), olfactory bulbs (B), hippocampus (C), and cerebral cortex (D) after intranasal or subcutaneous administration to mice. The intranasal Exendin-4 administration dose was 0.3125 mg/kg (2.5 mg/mL, 5 μL/40 g mouse) with or without L-penetratin (2 mM), and the subcutaneous injection dose was 0.125 mg/kg (0.05 mg/mL, 100 μL/40 g mouse) without L-penetratin. Data are expressed as the mean ± SEM of n = 3–5. * indicates a significant difference (p < 0.05) from the control intranasal administration group without L-penetratin.